Literature DB >> 24508113

A review of methylene blue treatment for cardiovascular collapse.

Jean C Y Lo1, Michael A Darracq1, Richard F Clark1.   

Abstract

BACKGROUND: Historically, methylene blue (MB) has been used for multiple purposes, including as an antidote for toxin-induced and hereditary methemoglobinemia, ifosfamide-induced encephalopathy, and ackee fruit and cyanide poisoning; as an aniline dye derivative, antimalarial agent, and antidepressant. DISCUSSION: Most recently, the use of MB has been advocated as a potential adjunct in the treatment of shock states. Our article reviews the role of MB in septic shock, anaphylactic shock, and toxin-induced shock. MB is proposed to increase blood pressure in these shock states by interfering with guanylate cyclase activity, and preventing cyclic guanosine monophosphate production and vasodilatation.
SUMMARY: MB may be an adjunct in the treatment of septic shock, anaphylactic shock, and toxin-induced shock.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anaphylactic shock; methylene blue; septic shock; shock due to toxin

Mesh:

Substances:

Year:  2014        PMID: 24508113     DOI: 10.1016/j.jemermed.2013.08.102

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  24 in total

Review 1.  Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies.

Authors:  Andis Graudins; Hwee Min Lee; Dino Druda
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

2.  Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome.

Authors:  Betty S Chan; Therese Becker; Angela L Chiew; Ahmed M Abdalla; Tom A Robertson; Xin Liu; Michael S Roberts; Nicholas A Buckley
Journal:  J Med Toxicol       Date:  2017-11-13

3.  A severe case of vasoplegic shock following metformin overdose successfully treated with methylene blue as a last line therapy.

Authors:  Rachel Erin Graham; Michaela Cartner; James Winearls
Journal:  BMJ Case Rep       Date:  2015-07-06

4.  A fully battery-powered inexpensive spectrophotometric system for high-sensitivity point-of-care analysis on a microfluidic chip.

Authors:  Maowei Dou; Juan Lopez; Misael Rios; Oscar Garcia; Chuan Xiao; Michael Eastman; XiuJun Li
Journal:  Analyst       Date:  2016-05-04       Impact factor: 4.616

5.  Measuring In Vivo Free Radical Production by the Outer Retina.

Authors:  Bruce A Berkowitz; Bryce X Bredell; Christopher Davis; Marijana Samardzija; Christian Grimm; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

Review 6.  Current and novel mapping substances in gynecologic cancer care.

Authors:  Lea A Moukarzel; Jacqueline Feinberg; Evan J Levy; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2020-01-17       Impact factor: 3.437

Review 7.  Methylene blue and its analogues as antidepressant compounds.

Authors:  Anzelle Delport; Brian H Harvey; Anél Petzer; Jacobus P Petzer
Journal:  Metab Brain Dis       Date:  2017-07-31       Impact factor: 3.584

Review 8.  Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.

Authors:  Paulo Roberto Barbosa Evora; Lafaiete Alves Junior; Cesar Augusto Ferreira; Antônio Carlos Menardi; Solange Bassetto; Alfredo José Rodrigues; Adilson Scorzoni Filho; Walter Vilella de Andrade Vicente
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar

9.  Refractory Vasoplegic Syndrome in an Adult Patient with Infective Endocarditis: A Case Report and Literature Review.

Authors:  Seyed Mohsen Mirhosseini; Ali Sanjari Moghaddam; Paritash Tahmaseb Pour; Ali Dabbagh
Journal:  J Tehran Heart Cent       Date:  2017-01

10.  2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines.

Authors:  F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh
Journal:  World Allergy Organ J       Date:  2015-10-28       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.